Effect of Simvastatin on Alcohol Induced Hepatitis in Experimental Rat

Abstract

factors for liver diseases. There are currently no Food and Drug Administration FDA-approved drugs to prevent or cure alcohol-induced liver disease (ALD) at any stage. Consequence, therapeutic solutions are still a key requirement for those patients. The current study was intended to evaluate the effect of simvastatin in ethanol induced hepatitis and its progression. We demonstrated that chronic drinking of ethanol significantly elevated liver enzymes which were decrease upon simvastatin treatment, indicating its ameliorative effect. TG level was increased in alcohol induced hepatitis group when compared to normal control group and supplementation with simvastatin showed insignificant decrease of serum TG. However, there is insignificant change in the serum total cholesterol in the present model of alcohol induced hepatitis and the results represent the reversal of hypercholesteremia after 55 days. These results suggest simvastatin could prove not beneficial in the prevention or treatment of ALD.